Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Documented chronic HCV infection (diagnosis of hepatitis C \>= 6 months before the screening period)~* HCV geno- and subtype of 1a or 1b (Panel 1) or 1b (Panels 2 and 3)~* Patient has never received pegylated interferon, ribavirin, or any other approved or investigational antiviral treatment for chronic HCV infection~* Patient with HCV ribonucleic acid (RNA) level of \>100,000 IU/mL at screening (as assessed by standard quantitative in vitro nucleic acid amplification assay)~* A Body Mass Index (BMI, weight in kg divided by the square of height in meters) of 18.0 to 32.0 kg/m2, extremes included~* A body weight above 50 kg~* Normal 12-lead electrocardiogram (ECG) at screening~Exclusion Criteria:~* Evidence of or documented liver cirrhosis~* Evidence of decompensated liver disease~* Evidence of any other cause of significant liver disease in addition to hepatitis C~* History or evidence of current use of alcohol, barbiturate, amphetamine, recreational or narcotic drug use, which in the Investigator's opinion would compromise patient's safety and/or compliance with the study procedures~* A positive urine drug (with exclusion of methadone or equivalent) test at study screening~* Patient with protocol-defined laboratory abnormalities at screening~* Patient coinfected with HIV-1 or HIV-2, or hepatitis A or B virus infection, or active tuberculosis at study screening~* Patient infected/coinfected with non-genotype 1 HCV at study screening~* Patient with any cardiac disease at screening, or any active clinically significant disease (eg, cardiac dysfunction, cardio(myo)pathy, cardiac insufficiency), or medical history or physical examination findings during screening that, in the Investigator's opinion, would compromise the outcome of the trial~* Patient having uncontrolled/unstable disease such as diabetes, epilepsy, a manifest psychiatric disease, or thyroid disease or disorders~* Patient with non-stable methadone (or equivalent drug) use

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Panel 1 (Type: EXPERIMENTAL): Study participants will receive double-blind treatment with JNJ-47910382 30 mg or matching placebo. Participants in each of Panel will be treated sequentially (ie, participants in Panel 1 will be treated before participants in Panel 2, participants in Panel 2 will be treated before participants in Panel 3).
- Panel 2 (Type: EXPERIMENTAL): Study participants will receive double-blind treatment with JNJ-47910382 90 mg or matching placebo. Participants in each of Panel will be treated sequentially.
- Panel 3 (Type: EXPERIMENTAL): Study participants will receive double-blind treatment with JNJ-47910382 200 mg (maxiumum dose) or matching placebo. Participants in each of Panel will be treated sequentially.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility